https://scholars.lib.ntu.edu.tw/handle/123456789/551042
標題: | Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis | 作者: | CHEN-HUA LIU Peng C.-Y. YU-JEN FANG Kao W.-Y. Yang S.-S. Lin C.-K. Lai H.-C. Su W.-P. Fang S.-U. Chang C.-C. TUNG-HUNG SU CHUN-JEN LIU PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2020 | 出版社: | Nature Research | 卷: | 10 | 期: | 1 | 來源出版物: | Scientific Reports | 摘要: | Data regarding the efficacy and tolerability of elbasvir/grazoprevir (EBR/GZR) for East-Asian hepatitis C virus genotype 1b (HCV GT1b) patients receiving hemodialysis were limited. We prospectively recruited 40 HCV GT1b hemodialysis patients who received EBR/GZR for 12 weeks at 6 academic centers in Taiwan. The efficacy endpoints were sustained virologic response 12 weeks off-therapy (SVR12) by intention-to-treat (ITT) modified ITT (mITT) analyses. Patients’ baseline characteristics, early viral kinetics and HCV resistance-associated substitutions (RASs) at HCV non-structural 3 and 5 A (NS3 and NS5A) regions potentially affecting SVR12 were analyzed. The tolerability for EBR/GZR was also assessed. The SVR12 rates by ITT and mITT analyses were 95% (38 of 40 patients; 95% confidence interval (CI): 83.5–98.6%) and 100% (38 of 38 patients; 95% CI: 90.8–100%), respectively. Patients’ baseline characteristics, on-treatment viral decline, and baseline HCV RASs did not affect SVR12. All patients tolerated treatment well. Among 5 patients who had serious adverse events (AEs) including one death due to on-treatment suicide and the other death due to off-therapy acute myocardial infarction, none of these events were judged related to EBR/GZR. The common AEs included upper respiratory tract infection (7.5%), fatigue (5.0%) and anorexia (5.0%). Nine (22.5%) and 8 (20.0%) patients had on-treatment hemoglobin levels of 9.0–10.0 g/dL and 7.0–9.0 g/dL. Three (7.5%) patients had on-treatment elevated alanine aminotransferase (ALT) quotient > 2.5, in whom one (2.5%) had EBR/GZR-induced late ALT elevation. No patients developed hyperbilirubinemia or hepatic decompensation. In conclusion, treatment with EBR/GZR is effective and well-tolerated for East-Asian HCV GT1b patients receiving hemodialysis. ? 2020, The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086147191&doi=10.1038%2fs41598-020-66182-8&partnerID=40&md5=34bd29539b41762d4a5bef97fd9ee73b https://scholars.lib.ntu.edu.tw/handle/123456789/551042 |
ISSN: | 2045-2322 | DOI: | 10.1038/s41598-020-66182-8 | SDG/關鍵字: | 2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole; amide; antivirus agent; benzofuran derivative; carbamic acid derivative; cyclopropane derivative; grazoprevir; imidazole derivative; quinoxaline derivative; sulfonamide; adverse event; antiviral resistance; Asian continental ancestry group; chronic hepatitis C; combination drug therapy; drug effect; female; genotype; hemodialysis; Hepacivirus; human; male; middle aged; procedures; sustained virologic response; Amides; Antiviral Agents; Asian Continental Ancestry Group; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Renal Dialysis; Sulfonamides; Sustained Virologic Response |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。